Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3…
Leading Provider of Evidence-Based Mental Health Treatment Brings Services to West LALOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Guidelight,…
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well…
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel…
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company…
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau…
Mount Sinai and BPGbio scientists uncover novel molecular drivers from live brain samples that direct human brain structure and function…
Repairon expands to North America to Accelerate Clinical Trials and Product DevelopmentGÖTTINGEN, Germany, Feb. 02, 2026 (GLOBE NEWSWIRE) -- German…
ANTWERP, Belgium, February 2, 2026 (GLOBE NEWSWIRE) – AgomAb Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel…
Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE)…